approval
saveERLEADA (APALUTAMIDE) — FDA approval
community read0 votes
Sponsor: JANSSEN BIOTECH. Form: TABLET. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalERLEADA (APALUTAMIDE) — FDA approvalAug 2, 2024 · 793d ago
- approvalERLEADA (APALUTAMIDE) — FDA approvalJul 9, 2024 · 817d ago
- approvalERLEADA (APALUTAMIDE) — FDA approvalDec 19, 2023 · 1020d ago
- approvalERLEADA (APALUTAMIDE) — FDA approvalFeb 17, 2023 · 1325d ago
- approvalERLEADA (APALUTAMIDE) — FDA approvalNov 8, 2022 · 1426d ago
- approvalERLEADA (APALUTAMIDE) — FDA approvalNov 8, 2022 · 1426d ago
- approvalERLEADA (APALUTAMIDE) — FDA approvalApr 26, 2022 · 1622d ago
- approvalERLEADA (APALUTAMIDE) — FDA approvalSep 7, 2021 · 1853d ago
same company · ±60 days · 6
- approvaltalquetamab: TALVEY (TALQUETAMAB-TGVS) — FDA approvalMar 5, 2026
- approvalteclistamab: TECVAYLI (TECLISTAMAB-CQYV) — FDA approvalMar 5, 2026
- approvalicotrokinra hydrochloride: ICOTYDE (ICOTROKINRA HYDROCHLORIDE) — FDA approvalMar 17, 2026
- approval(amivantamab + hyaluronidase (human recombinant)): RYBREVANT FASPRO (AMIVANTAMAB AND HYALURONIDASE-LPUJ) — FDA approvalFeb 13, 2026
- approval(daratumumab + hyaluronidase (human recombinant)): DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalFeb 12, 2026
- approval(daratumumab + hyaluronidase (human recombinant)): DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalJan 27, 2026
comments(0)
5-min edit window · permanent after that